MedPath

GLP DLax

GLP-DLax Tablets

Approved
Approval ID

28316b4d-3a83-4b66-9483-dc5613733111

Product Type

DIETARY SUPPLEMENT

Effective Date

Jun 16, 2025

Manufacturers
FDA

Basiem, LLC

DUNS: 079686680

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Inulin, Slippery Elm, Cape Aloe, Cascara sagrada, Cholecalciferol, Folic acid

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code69597-362
Product Classification
G
Generic Name
Inulin, Slippery Elm, Cape Aloe, Cascara sagrada, Cholecalciferol, Folic acid
Product Specifications
Route of AdministrationORAL
Effective DateJune 16, 2025
FDA Product Classification

INGREDIENTS (10)

BLUE AGAVE INULIN (AGAVE TEQUILANA)Active
Quantity: 500 mg in 1 1
Code: PW973NF38H
Classification: ACTIB
ELMActive
Quantity: 425 mg in 1 1
Code: 63POE2M46Y
Classification: ACTIB
ALOE FEROX LEAFActive
Quantity: 225 mg in 1 1
Code: 0D145J8EME
Classification: ACTIB
RHAMNUS CATHARTICA BARKActive
Quantity: 135 mg in 1 1
Code: KD27950XHY
Classification: ACTIB
FOLIC ACIDActive
Quantity: 1 mg in 1 1
Code: 935E97BOY8
Classification: ACTIB
CHOLECALCIFEROLActive
Quantity: .125 mg in 1 1
Code: 1C6V77QF41
Classification: ACTIB
CELLULOSE ACETATEInactive
Code: 3J2P07GVB6
Classification: IACT
CALCIUM STEARATEInactive
Code: 776XM7047L
Classification: IACT
CALCIUM PHOSPHATEInactive
Code: 97Z1WI3NDX
Classification: IACT
SILICAInactive
Code: ETJ7Z6XBU4
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 6/16/2025

GLP-DLAX LABEL:

PRINCIPAL DISPLAY PANEL - 30 Capsule Bottle Label![PRINCIPAL DISPLAY PANEL - 30 Capsule Bottle Label](/dailymed/image.cfm?name=GLP- DLax+Label.jpg&id=882086)Label:

PRINCIPAL DISPLAY PANEL - 30 Capsule Bottle Label

PRECAUTIONS SECTION

LOINC: 42232-9Updated: 5/19/2025

SAFE HANDLING

CONTRAINDICATIONS
This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. GLP-DLax is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.

WARNINGS AND PRECAUTIONS
Tell your doctor if you have kidney problems or thyroid disease. Do not use this product if you have abdominal pain, diarrhea, or loose stools. Rectal bleeding and/or failure to have a bowel movement after the use of a laxative formula may be an indication of a more serious condition. Should this occur, or if you have a known medical condition and are taking this medication, consult your healthcare provider about the risks and benefits prior to taking this or any dietary supplement.

Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient. Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.

ADVERSE REACTIONS
Allergic sensitization has been reported following both oral and parenteral administration of folic acid.
You should call your doctor for medical advice about serious adverse events. To report adverse side effects or to obtain product information, contact Basiem, LLC, at 1-844-551-9911.

KEEP OUT OF REACH OF CHILDREN

HEALTH CLAIM SECTION

LOINC: 69719-3Updated: 5/22/2025

HOW SUPPLIED HEALTH CLAIM

GLP-DLax, Metabolic Support

Dietary Supplement

Vegan tablets are light brown and have an oval shape

Bottles contain 30 Tablets 69597-362-30*

Manufactured in USA for:
Basiem, LLC

Madisonville, LA 70447

Rev. 05/2025

*Basiem does not represent these product codes to be National Drug Codes (NDC). Product codes are formatted according to standard industry practice, to meet the formatting requirement by pedigree reporting and supply-chain control including pharmacies.

Dispensed by Prescription**†**All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision.

This product is a prescription-folate with or without other dietary ingredients that – due to increased folate levels increased risk associated with masking of B12 deficiency (pernicious anemia) requires administration under the care of a licensed medical practitioner (61 FR 8760).1-3 The most appropriate way to ensure pedigree reporting consistent with these regulatory guidelines and safety monitoring is to dispense this product only by prescription (Rx). This is not an Orange Book product. This product may be administered only under a physician’s supervision and all prescriptions using this product shall be pursuant to state statutes as applicable. The ingredients, indication or claims of this product are not to be construed to be drug claims.

1. Federal Register Notice of August 2, 1973 (38 FR 20750)
2. Federal Register Notice of October 17, 1980 (45 FR 69043, 69044)
3. Federal Register Notice of March 5, 1996 (61 FR 8760)

DOSAGE & ADMINISTRATION SECTION

LOINC: 34068-7Updated: 5/22/2025

DOSAGE

Take two tablets once or twice daily with 8-12 oz of water or as directed by a healthcare practitioner.

STATEMENT OF IDENTITY SECTION

LOINC: 69718-5Updated: 6/16/2025

STATEMENT OF IDENTITY

GLP-DLax Tablets 69597-362-30*

Dietary Supplemement

Dispensed by Prescription

** Amount Per Serving (2 tablets):**

** %DV**

Vitamin D (as cholecalciferol)

250 mcg

(10,000 IU)

1250%

Folate (from 2,000 mcg Folic Acid)

3,334 mcg

DFE

834%

Inulin (from organic agave (heart) extract) 1,000 mg *

Slippery Elm (bark) 850 mg *

Aloe Vera (leaf) 450 mg *

Cascara sagrada (bark) 270 mg *

*Daily Values (DV) not established

OTHER INGREDIENTS: Cellulose, calcium stearate, calcium phosphate, silica

GLP-DLax capsules are an orally administered prescription vitamin formulation for the clinical dietary management of suboptimal nutritional status in patients where advanced supplementation is required and for patients with occasional constipation to restore and maintain regularity.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent disease.

GLP-DLax is manufactured in accordance with Current Good Manufacturing Practice for foods, using ingredients that have been approved by the U.S. Food and Drug Administration (FDA) as food additives or are “Generally Recognized as Safe” (GRAS) for their intended use.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

GLP DLax - FDA Drug Approval Details